Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

74.17
-1.1800-1.57%
Post-market: 74.170.00000.00%19:30 EDT
Volume:327.76K
Turnover:24.40M
Market Cap:1.70B
PE:16.34
High:75.81
Open:75.31
Low:74.08
Close:75.35
52wk High:99.50
52wk Low:70.15
Shares:22.97M
Float Shares:20.28M
Volume Ratio:1.10
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.54
EPS(LYR):3.32
ROE:20.46%
ROA:5.45%
PB:2.85
PE(LYR):22.34

Loading ...

ANI Pharmaceuticals Says US FDA Approves Isosorbide Mononitrate Tablet

MT Newswires Live
·
Apr 08

ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet

THOMSON REUTERS
·
Apr 08

ANI Pharmaceuticals replaces EisnerAmper with Ernst & Young as auditor

Reuters
·
Apr 08

ANI publishes Phase 4 NEW DAY ILUVIEN DME trial results in Ophthalmology journal

Reuters
·
Apr 07

ANI Pharmaceuticals Announces Publication of New Day Clinical Trial Results in Ophthalmology

THOMSON REUTERS
·
Apr 07

ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology

GlobeNewswire
·
Apr 07

ANI Pharmaceuticals (ANIP) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 25

Barclays Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Mar 19

Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story

Simply Wall St.
·
Mar 18

ANI Pharmaceuticals Head of Rare Disease Christopher Mutz Disposes of Common Shares

Reuters
·
Mar 14

ANI Pharmaceuticals Sr. VP, General Counsel and Secretary Meredith Cook Disposes of Common Shares

Reuters
·
Mar 14

ANI Pharmaceuticals Head of Rare Disease Christopher Mutz Disposes of Common Shares

Reuters
·
Mar 05

ANI Pharmaceuticals SVP, Generics Ori Gutwerg Disposes of Common Shares

Reuters
·
Mar 05

ANI Pharmaceuticals Director Patrick D. Walsh Disposes of Common Shares

Reuters
·
Mar 04

ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors

TIPRANKS
·
Mar 03

ANI Pharmaceuticals Publishes Corporate Presentation on Rare Disease Growth Strategy and 2026 Revenue Outlook

Reuters
·
Mar 03

ANI Pharmaceuticals Signals Strong Growth in 2025 Call

TIPRANKS
·
Mar 02

Does Record 2025 Profitability and Reaffirmed 2026 Outlook Change The Bull Case For ANI Pharmaceuticals (ANIP)?

Simply Wall St.
·
Mar 01

H.C. Wainwright Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Feb 28

Stock Track | ANI Pharmaceuticals Plummets 5.17% Intraday Despite Strong Earnings as Health Care Sector Weakens

Stock Track
·
Feb 28